Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma 340Lymphoma, Non-Hodgkin 295Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Leukemia, Lymphocytic, Chronic, B-Cell 235Lymphoma, Large B-Cell, Diffuse 217Leukemia 186Lymphoma, Follicular 183Lymphoma, Mantle-Cell 167Recurrence 142Hodgkin Disease 141Lymphoma, B-Cell 139Leukemia, Myeloid, Acute 133Burkitt Lymphoma 120Lymphoma, B-Cell, Marginal Zone 94Multiple Myeloma 86Myelodysplastic Syndromes 83Waldenstrom Macroglobulinemia 62Lymphoma, T-Cell, Peripheral 57Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 52Neoplasms 52Lymphoma, T-Cell, Cutaneous 52Hematologic Neoplasms 49Lymphoma, Large-Cell, Anaplastic 43Lymphoma, T-Cell 41Lymphoma, Large-Cell, Immunoblastic 41Leukemia, Myelogenous, Chronic, BCR-ABL Positive 40Mycosis Fungoides 38Leukemia, B-Cell 34Sezary Syndrome 30Myeloproliferative Disorders 29

Interventions

rasburicase 1alvocidib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Tumor Lysis Syndrome × Lymphoid × Clear all
NCT00445341 2018-01-30

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
28 enrolled 10 charts
Lymphoid

Lymphoma, Tumor Lysis Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00360438 2012-08-01

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

M.D. Anderson Cancer Center

Phase 1/2 Completed
18 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡